Different anthracycline derivates for reducing cardiotoxicity in cancer patients
Author:
Publisher
John Wiley & Sons, Ltd
Link
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005006.pub2/epdf/full
Reference84 articles.
1. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer;Batist;Journal of Clinical Oncology,2001
2. Phase II study of doxorubicin versus epirubicin in advanced breast cancer;Brambilla;Cancer Treatment Reports,1986
3. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer;Chan;Annals of Oncology,2004
4. A prospective randomized pahase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin;Journal of Clinical Oncology,1988
5. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer, a randomized clinical trial;Gasparini;American Journal of Clinical Oncology,1991
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy;Russian Journal of Cardiology;2021-10-19
2. Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention;Clinical and Translational Oncology;2017-03-24
3. The Role of Liposomal Anthracyclines in Metastatic Breast Cancer;Current Breast Cancer Reports;2013-01-10
4. The use of liposomal anthracycline analogues for childhood malignancies: A systematic review;European Journal of Cancer;2011-09
5. Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment;Cancer Treatment Reviews;2011-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3